BioMarin

In News

BioMarin to acquire Amicus for $14.50 per share in cash, or $4.8B - MSN

MSN - Jan 10, 2026

Veeva and BioMarin Form Long-Term Strategic Partnership - PR Newswire

PR Newswire - Jan 08, 2026

BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook - BioMarin Pharmaceutical

BioMarin Pharmaceutical - Dec 19, 2025

Veeva, BioMarin Enter Long-Term Strategic Partnership - Contract Pharma

Contract Pharma - Jan 08, 2026

BioMarin quietly discards liver disease candidate after $4.8B Amicus announcement - Fierce Biotech

Fierce Biotech - Dec 22, 2025

BioMarin fends off Kuvan generics competition again - The Pharma Letter

The Pharma Letter - Jan 08, 2026

Is BioMarin (BMRN) Pricing Reflect Long-Term Value After Rare Disease Pipeline Progress? - simplywall.st

simplywall.st - Jan 09, 2026

Veeva Systems Expands Long-Term Partnership With BioMarin Pharmaceutical - Nasdaq

Nasdaq - Jan 08, 2026

Veeva and BioMarin form strategic partnership to accelerate therapies - Investing.com

Investing.com - Jan 08, 2026

BioMarin makes its largest-ever transaction, paying $4.8B for fellow rare disease drugmaker Amicus - Fierce Pharma

Fierce Pharma - Dec 19, 2025

BioMarin to acquire Amicus Therapeutics for $4.8 billion in rare disease bet - CNBC

CNBC - Dec 19, 2025

BioMarin CEO says $4.8 billion Amicus deal will lead to cost savings and revenue growth - statnews.com

statnews.com - Dec 19, 2025

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment